Vistagen Therapeutics reported a narrower first-quarter fiscal 2027 net loss of $13.0 million, or $0.30 per share, compared with $15.1 million, or $0.47 per share, a year earlier. Revenue was $1.2 million, primarily from the expiration of the exclusivity period under its agreement with Fuji Pharma. The company said it is preparing to engage with the FDA during the current quarter regarding a potential future Phase 3 registration-directed development pathway for fasedienol in social anxiety disorder. Vistagen also received an FDA "Study May Proceed" letter for refisolone for moderate-to-severe menopausal vasomotor symptoms. Cash, cash equivalents and marketable securities totaled $31.7 million as of June 30, 2026, which the company expects to fund operations into 2027 but not for more than one year.
VistaGen Therapeutics IncNarrower Q1 loss and cash runway into 2027, with FDA engagement planned for fasedienol.
Fuji Pharma Co., Ltd.